Recent discussions on X about X4 Pharmaceuticals (XFOR) have been buzzing with activity following the company's announcement of a $60 million private placement financing and significant leadership changes. Many users are pointing to the stock's sharp rise of over 30% in a single day as a sign of strong investor confidence. The chatter also highlights the potential momentum from the firm's Phase 3 drug candidate, which has received FDA Fast Track designation.
While optimism dominates, some participants on X express caution, noting the high short interest and volatile market conditions surrounding small-cap biotech stocks like XFOR. Posts reflect a mix of excitement over the fresh capital and new board members, with others debating whether the rally can sustain itself. This blend of enthusiasm and skepticism keeps the conversation lively and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
X4 Pharmaceuticals Insider Trading Activity
X4 Pharmaceuticals insiders have traded $XFOR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $XFOR stock by insiders over the last 6 months:
- MARK BALDRY (Chief Commercial Officer) purchased 1,032 shares for an estimated $2,561
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
X4 Pharmaceuticals Hedge Fund Activity
We have seen 27 institutional investors add shares of X4 Pharmaceuticals stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PALE FIRE CAPITAL SE added 1,988,630 shares (+4255.4%) to their portfolio in Q1 2025, for an estimated $14,103,363
- POINT72 ASSET MANAGEMENT, L.P. added 628,333 shares (+2900.0%) to their portfolio in Q1 2025, for an estimated $4,456,137
- GOLDMAN SACHS GROUP INC removed 468,510 shares (-98.1%) from their portfolio in Q1 2025, for an estimated $3,322,672
- MILLENNIUM MANAGEMENT LLC added 250,134 shares (+2900.1%) to their portfolio in Q1 2025, for an estimated $1,773,950
- UBS GROUP AG added 137,138 shares (+445.7%) to their portfolio in Q1 2025, for an estimated $972,582
- ALLIANCEBERNSTEIN L.P. added 105,918 shares (+2900.3%) to their portfolio in Q1 2025, for an estimated $751,170
- AQR CAPITAL MANAGEMENT LLC added 86,069 shares (+9627.4%) to their portfolio in Q1 2025, for an estimated $610,401
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
X4 Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $XFOR in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 05/02/2025
- Cantor Fitzgerald issued a "Overweight" rating on 03/26/2025
To track analyst ratings and price targets for X4 Pharmaceuticals, check out Quiver Quantitative's $XFOR forecast page.
X4 Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $XFOR recently. We have seen 2 analysts offer price targets for $XFOR in the last 6 months, with a median target of $46.75.
Here are some recent targets:
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $3.5 on 08/13/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $90.0 on 03/26/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
